NEW YORK (360Dx) – Inotrem said today that it has entered an R&D agreement with Roche Diagnostics to collaborate on developing a companion diagnostic test for a septic shock treatment in clinical trials.

Under the terms of the agreement, Roche and Inotrem will develop a prototype assay for quantitative measurement of soluble plasma circulating protein (sTREM-1) in septic shock patient samples. The test would run on Roche's Elecsys immunochemistry platform.

Financial and other terms of the agreement were not disclosed.